Mardepodect

Research use only, not for human use.

A potent and selective PDE10A inhibitor with IC50 of 0.37 nM.

A potent and selective PDE10A inhibitor with IC50 of 0.37 nM; displays >1,000-fold selectivity over the PDEs; antagonizes apomorphine-induced climbing in mice, inhibits conditioned avoidance responding in both rats and mice, and blocks NMDA antagonist-induced deficits in prepulse inhibition of acoustic startle response in rats; dose-dependently increases c-Fos immunopositive nuclei in all regions of neostriatum in the DRd1a-tdTomato mice; improves cortico-basal ganglia function in huntington's disease models; orally bioavailable.Schizophrenia Phase 2 Discontinued.

——

In the conditioned avoidance response assay (CAR), Mardepodect (PF-2545920) is active with an ED50 of 1 mg/kg. Administration of Mardepodect (PF-2545920) to mice causes a dose dependent increase in striatal cGMP.

Mardepodec | MP-10 | PF-02545920

Angiogenesis

PDE

PDE

Neurological Disease

Schizophrenia

898562-94-2

392.45

C25H20N4O

>98% (HPLC)

DMSO: ≥ 45 mg/mL

CN1N=C(C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C(C5=CC=NC=C5)=C1

Quinoline, 2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-

(-20℃)

With Ice Pack

≥ 2 years